The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

Devices and methods for nasal administration of a pharmaceutical composition. In certain embodiments, the devices comprises a reservoir, a conduit in fluid communication with the reservoir, and an anatomic positioning device configured to position the conduit in a nasal cavity of a user. Particular embodiments include an actuator configured to transfer the pharmaceutical composition from the reservoir to the conduit and emit the pharmaceutical composition from the conduit.

Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.

A pharmaceutical composition is described. The composition comprises: (i) a drug component consisting of salmeterol xinafoate and fluticasone propionate. and (ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition.

A pain relieving aerosol spray (pain relieving and pain preventing aerosol spray) comprising a pain relieving composition and at least one refrigerant, wherein the pain relieving aerosol spray is capable of providing rapid onset local anaesthesia of intact skin and/or a wound of a subject to which it is applied and further pain relief due to the pain relieving composition remaining on the wound of the subject. The pain relieving composition comprises a liquid gel matrix that contains at least one anaesthetic agent, a vasoconstrictor, and an antiseptic agent. The spray can be used for a surgical procedure or animal husbandry procedure, such as castration or branding, or treating a burn or wound.

The two devices described allow for greater control over application of a fibrin biopolymer and yet remain simple enough to be used by both medical personnel and by non-medical workers. One of the devices includes chambers where components necessary for formation of a fibrin biopolymer are stored and are pushed by plungers connected to an actuator upon the actuator receiving pressure from the user, with the components mixing in a chamber within the device and flowing out of a tube connected to the mixing chamber before formation of the fibrin biopolymer is completed. The other device dispenses formulations that include components necessary for formations of a fibrin biopolymer onto a skin of a patient using one or more propellants, with the formation of the fibrin biopolymer being initiated after the formulations are dispensed on the patient's skin and are intentionally mixed together.

A liquid composition comprising witch hazel; glycerin; dehydrated xanthan gum; and water.

Provided herein are oronasal formulations including a cannabinoid and N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM). Also provided are methods of using the formulations.

Formulations and pressurized devices able to get Ivermectin concentrations in the micromolar range in the upper and lower respiratory tract and the oropharyngeal cavity are disclosed. The formulations and devices are used for the prevention or treatment of respiratory diseases caused by SARS CoV 2, such as pandemic COVID 19, and other viruses for which Ivermectin exerts viral inactivation at this concentration range.

An apparatus produces medical foam for wound care or hair stimulation. The apparatus includes a foam generation unit having a fluid reservoir, a fluid delivery line and a foam generation tip. The apparatus also includes a compressed gas unit having at least one container of compressed gas, a source of electric power, and a gas regulator valve. A supply of wound care or hair stimulating solution is communicably connected to the foam generation tip such that when the apparatus is operated the medical foam is produced by the foam generator tip.